Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity.
A fast gradient HPLC method (cycle time 15 min) has been developed to determine Human Serum Albumin (HSA) binding of discovery compounds using chemically bonded protein stationary phases. The HSA binding values were derived from the gradient retention times that were converted to the logarithm of the equilibrium constants (logK HSA) using data from a calibration set of molecules. The method has been validated using literature plasma protein binding data of 68 known drug molecules. The method is fully automated, and has been used for lead optimization in more than 20 company projects. The HSA binding data obtained for more than 4000 compounds were suitable to set up global and project specific quantitative structure binding relationships that helped compound design in early drug discovery. The obtained HSA binding of known drug molecules were compared to the Immobilized Artificial Membrane binding data (CHI IAM) obtained by our previously described HPLC-based method. The solvation equation approach has been used to characterize the normal binding ability of HSA, and this relationship shows that compound lipophilicity is a significant factor. It was found that the selectivity of the "baseline" lipophilicity governing HSA binding, membrane interaction, and octanol/water partition are very similar. However, the effect of the presence of positive or negative charges have very different effects. It was found that negatively charged compounds bind more strongly to HSA than it would be expected from the lipophilicity of the ionized species at pH 7.4. Several compounds showed stronger HSA binding than can be expected from their lipophilicity alone, and comparison between predicted and experimental binding affinity allows the identification of compounds that have good complementarities with any of the known binding sites.
Valko
Klara
K
Computational, Analytical and Structural Sciences, GlaxoSmithKline, Gunnels Wood Road Stevenage, Herts. SG1 2NY United Kingdom. Klara.L.Valko@gsk.com
Nunhuck
Shenaz
S
Bevan
Chris
C
Abraham
Michael H
MH
Reynolds
Derek P
DP
D001798:Blood Proteins / Q000378:metabolism; D002138:Calibration; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002845:Chromatography; D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008567:Membranes, Artificial; D000442:Octanols / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D012709:Serum Albumin / Q000737:chemistry*; D013816:Thermodynamics; D014867:Water / Q000737:chemistry
D001798:Blood Proteins; D008055:Lipids; D008567:Membranes, Artificial; D000442:Octanols; D004364:Pharmaceutical Preparations; D012709:Serum Albumin; D014867:Water